Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by general360on Jul 26, 2019 2:31pm
164 Views
Post# 29965028

NLRP3 & RVX-208?

NLRP3 & RVX-208?
Topcoin said " it's in the Its in the Table of the Poster on monocyte adhesion / endothelial cells etc" and voila!

https://www.resverlogix.com/upload/media_element/168/2d3efd79784a/vascular-discovery-2019-vi-bioinformatics-poster.pdf

NLRP downregulated by 44%

another indication?  and possibly available quite a bit sooner than the drug in question?

Go RVX Go!!!


someone else posted on agora about having a request for their shares to lend out.  someone else picked up the thread sayin its for covering.    i dont think that's for covering?  How are they gonna borrow shares which are owned, sell them to someone who's gonna cover?  no, imho those shares are being borrowed for shorting.... i had a similar request last year from etrade which i ignored.....and my co-worker is still not able to place online trade for rvxcf via the schwab. he spoke to the broker and was told there are liquidity problems...looks like others may be seeing it too...
Bullboard Posts